Intel applies nanotechnology expertise to disease detection:
This article was originally published in Clinica
Intel has teamed up with a US institution to apply its expertise in nanotechnology to develop improved methods of studying, diagnosing and preventing cancer. The company is building an Intel Raman bioanalyser system at the Fred Hutchinson Cancer Research Center, in Seattle, to determine whether the technology, previously used to detect microscopic imperfections on silicon chips, can also detect subtle traces of disease. The instrument beams lasers onto medical samples, such as serum, to create images that reveal the chemical structure of molecules. The research could lead to a new era of molecular diagnostics and improved methods of early disease detection, the company said.